Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer. NCCP National SACT Regimen. HSE.

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
HER2 positive metastatic breast cancer (MBC) as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.	1
HER2 positive metastatic breast cancer (MBC) in combination with PACLitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.	1
HER2 positive metastatic breast cancer (MBC) in combination with DOCEtaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.	1
HER2 positive metastatic breast cancer (MBC) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.	3

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
Sensitivity (+)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (+)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (+)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (+)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab